The FK+ Reintroduction.

There is a specific kind of cannabis company story that the industry does not tell well, because telling it well requires saying that somebody smart lost a great deal of other people's money. Flow Kana is that story. Between 2015 and 2022 it raised roughly $175 million, bought the former Fetzer winery in Redwood Valley and rechristened it the Flow Cannabis Institute, became the second-largest employer in Mendocino County after the hospital system, and made "sun-grown" a marketing category the whole California industry had to respond to. By January 2023 the operation was mothballed, the licences had lapsed, and the buildings were being leased out to other tenants.

FK+ is what the founders built next. Launched in May 2025 out of a Miami address, it is a national direct-to-consumer hemp brand selling gummies and pre-rolls in four effect lanes: SLEEP, RELAX, ENERGY, FOCUS. Michael Steinmetz and Flavia Cassani, who co-founded Flow Kana, are named as co-founders alongside Kevin Haslebacher. The site's Facebook link still points at facebook.com/flowkana. The Shopify store still lists "Flow Kana" as the product vendor. flowkana.com now redirects here.

We came to FK+ the way we came to BRĒZ in Volume 04 — looking for a brand that layers functional botanicals onto a precise cannabinoid base, the thing our two-module framework was written to evaluate. FK+ makes that claim more loudly and more specifically than any brand we have covered. It says its ingredients are present at "supplement grade dosing," at "therapeutic doses," at "clinically relevant levels." It says, in a graphic on its own science page, "No fairy dusting ever."

That is a testable claim. It is the exact claim the Botanical Module exists to test. So we tested it, and the answer splits cleanly in two: the cannabinoid formulation is genuinely, unusually good — better-engineered than anything else we have plotted — and the botanical claim cannot be checked at all, because FK+ publishes no dose for any botanical in any product, anywhere.

What happened to Flow Kana.

The background matters here, because FK+ is being introduced to an audience that mostly does not know it, and because the founders' previous company is a genuine landmark in the modern cannabis industry — both for its ambition and for how it ended.

Two things are worth stating precisely, because the looser versions circulate. There was no bankruptcy. We found no bankruptcy filing, no receivership, no assignment for the benefit of creditors, and no foreclosure for any Flow entity. There was also no WARN notice filed with California's Employment Development Department across four fiscal years of reports. What happened was slower and quieter than a collapse: a long unwind, an investor takeover, and a company that stopped operating without ever formally failing.

The reasons were structural as much as managerial. California's legal market in 2019–2022 was a bad place to be a high-capital, low-margin middleman: a punishing tax stack, a licensing regime that left most of the state without retail, and a thriving unlicensed market that faced none of those costs. Flow Kana's thesis — that the Emerald Triangle's small sun-grown farms could be aggregated into a premium branded supply chain — was a good thesis about a market that did not arrive on schedule.

The pivot nobody is describing plainly.

Flow Kana was a California state-licensed distributor selling state-legal cannabis inside California. FK+ ships hemp-derived products to 45–47 states by mail under the 2018 Farm Bill. Those are not adjacent business models; they are different industries with different regulators, different compliance surfaces, and different consumer protections.

The mechanism is worth spelling out, because FK+'s own lab results make it unusually legible. The Farm Bill defines hemp by delta-9 THC content on a dry-weight basis — 0.3% or less. It says nothing about THCa, the acidic precursor that converts to delta-9 THC when heated. So a flower can be federally compliant on paper and fully psychoactive in practice. Here is FK+'s own SLEEP pre-roll flower, from its own COA:

This is not a criticism of FK+ specifically — it is how essentially the entire national THCa flower market operates, and FK+ is more transparent about it than most, since the numbers are right there on a published COA. But a consumer reading "hemp-derived, Farm Bill compliant" in the site footer and concluding they are buying something mild is misreading the situation by about two orders of magnitude. A 24.9% total-THC pre-roll is a strong dispensary flower. The framework places it accordingly and so should the buyer.

Part one: the cannabinoid work is excellent.

Now the good news, and it is substantial. FK+'s gummy line is the most carefully constructed cannabinoid dose ladder we have plotted from any brand in this series — better than Ayrloom's, better than BRĒZ's. Four SKUs, four distinct cannabinoid stacks, four different total doses, and the doses ascend in a clean monotonic line from the lightest daytime product to the heaviest night one.

Read that variance column again. On the primary psychoactive — the number that actually determines whether a consumer has a good night or a bad one — FK+ lands within 2% of label on all four products. That is tighter than most licensed state-market edibles manage, and it is verified by a third-party ISO/IEC 17025-accredited lab rather than asserted. The minor cannabinoids run a little rich (CBG is 8–15% over label across the line), which is the direction you would rather see them err.

Part two: the botanical claim has no numbers.

FK+ names thirteen distinct botanicals across the four gummy SKUs. Turkey tail, valerian root and passionflower in SLEEP. Reishi, ashwagandha and lavender in RELAX. Cordyceps, green tea, maca root and yerba mate in ENERGY. Lion's mane, ginkgo biloba, yerba mate and rosemary in FOCUS. Each gets a paragraph of description on the product page and an illustrated icon. Each is positioned as an active contributor to the product's effect.

Every one of them appears on the supplement facts panel inside an "ADVANCED PROPRIETARY BLEND" with no individual milligram figure and no total blend weight. We looked on the product pages, the supplement facts panels, the COAs, the Science page, the blog, and the launch press release. There is no FAQ page. There is no dose for any botanical anywhere on any surface FK+ publishes.

This is worth sitting with, because it is a sharper version of the pattern we documented at BRĒZ in Volume 04. There, the Lion's Mane dose was published — 33 mg of a 7:1 extract — and the problem was that the brand marketed it as "2,200 mg" using wet mushroom weight. That is a disclosure framed misleadingly. FK+ is a different failure mode: the disclosure is simply absent, while the claim about it is louder.

A proprietary blend is a legitimate and legal formulation choice, and companies use them for real competitive reasons. But there is a tension between electing proprietary-blend confidentiality and simultaneously running "no fairy dusting" as a marketing line. The proprietary blend is precisely the mechanism by which fairy dusting is conventionally concealed in the supplement industry. Choosing the mechanism and then denying the practice puts a reader in a position where they must simply trust the brand — which is the position a published standard exists to make unnecessary.

One inference, clearly labelled as such.

We can put a loose physical bound on it. A two-gummy FK+ serving weighs about 10 grams and carries 7–8 grams of carbohydrate, 6 of which are sugar. If the ENERGY blend delivered clinical doses of its four named botanicals — cordyceps at 1,000 mg, maca at 1,500 mg, plus meaningful green tea and yerba mate — that stack alone would exceed 2.5 grams, roughly a quarter of the serving's total mass, in a confection that is already three-quarters sugar and gelling agents by weight.

That is physically possible. It is also unusual for a gummy, and it would be a genuinely notable formulation achievement worth advertising with the actual numbers. We are not asserting the doses are sub-clinical. We are noting that the one publicly checkable constraint — serving mass and macronutrient breakdown — makes clinical dosing of the full botanical roster tight rather than comfortable, and that FK+ could resolve the question entirely by publishing a panel.

The lab-transparency claims need tightening.

FK+ makes two specific claims about testing: "3x ISO Lab Tested" and "Every batch is verified 3x by accredited third-party labs." The second is the stronger one, and it is the one with problems.

All eight COAs we located come from one laboratory — Excelbis Labs of Santa Ana, California, ISO/IEC 17025:2017 accredited, licence C8-0000059-LIC. One accredited lab is fine and normal. But "three accredited third-party labs" describes something different from what is published, and we could not find a second or third lab's results anywhere.

More consequentially: the four gummy COAs have a blank Batch # field. A certificate of analysis with no batch number cannot be matched to a package in a customer's hand, which is the entire function of publishing one. That is difficult to reconcile with "every batch is verified." All eight COAs are dated 1–13 May 2025 — roughly fifteen months old at the time of writing — which suggests they are launch-batch documents rather than an ongoing per-batch record. There is no lab-results index page; we tried /pages/lab-results, /pages/coa, /pages/certificates and /pages/lab-testing, all of which 404. COAs are reachable only as individual per-product PDF links. The aggregate PDF linked from the Science page contains only the four flower COAs, not the gummy ones.

And one number that does not match.

The SLEEP pre-roll is marketed as "30% THCA + 10% CBN." The THCa figure is fine — the COA reads 28.14%, which rounds to 30% loosely but defensibly. The CBN figure does not survive contact with the document:

CBN is the entire pharmacological rationale for a sleep pre-roll. Advertising twice the amount the brand's own lab measured is the kind of error that undermines the rest of the transparency case — particularly for a company whose Science page opens with "Quality + efficacy + transparency is our obsession." We assume this is a stale marketing asset rather than an intent to mislead; a formulation changed, or a target spec got printed instead of a result. But it is on the live site, and the COA that contradicts it is linked from the same page.

Two smaller items for completeness. The SLEEP gummy COA shows substantial pesticide and mycotoxin blocks marked NR/NT — not reported, not tested — while the summary line reads "Pass"; a pass on an untested panel is a weaker statement than it appears. And the COA client address reads "FK+, Los Angeles, CA 92007," which is a Cardiff-by-the-Sea ZIP in San Diego County, not Los Angeles. Minor, but this is a document set whose purpose is precision.

What FK+ tells us about the category.

Three volumes into examining the cannabinoid-plus-botanical thesis — Ayrloom, BRĒZ, now FK+ — a pattern has hardened that is worth naming. Cannabinoid disclosure in this industry has become genuinely good. Botanical disclosure has not.

The reason is structural, not moral. Cannabinoids are regulated, tested, and quantified because a compliance regime requires it; the COA exists because the law made it exist. Botanicals in the same product fall under the dietary supplement framework, where proprietary blends are permitted and per-ingredient disclosure is optional. So the same company, in the same gummy, operates under two disclosure cultures at once — and consumers, reading one label, have no way to know the two halves are held to different standards.

That is the gap DankeSuper's two-module framework was built to make visible. It is why the Botanical Module scores undisclosed doses at zero: not because the ingredients don't work, but because a standard that accepts unquantified claims stops being a standard. FK+ is the clearest illustration yet, precisely because it does the cannabinoid half so well. The contrast within a single product is the argument.

We would like to update this piece. If FK+ publishes per-ingredient milligram doses for its proprietary blends, we will re-run the Botanical Module against the line, re-plot the quadrant leans, and revise the verdict on the record. The cannabinoid work here is good enough that the brand deserves the chance — and the founders, whatever happened in Mendocino, have demonstrably learned something about formulation between the first company and this one.